
Hypertensive disorders of pregnancy (HDPs), including preeclampsia and gestational hypertension, are strongly associated with maternal cardiac dysfunction during and after pregnancy. We hypothesized that maternal inflammation drives persistent postpartum cardiac maladaptation after HDPs. We conducted a prospective longitudinal study assessing cardiac function and circulating inflammatory profiles during pregnancy and 3–6 months postpartum, complemented by a preclinical mechanistic mouse model recapitulating key antenatal and postpartum immune and cardiac features of HDPs. Here we show that distinct antenatal inflammatory signatures, including elevated chemokines, correlated with adverse left ventricular structure and function 3–6 months postpartum, despite resolution of systemic inflammation. Mechanistically, our preclinical HDP mouse model demonstrates that reduced antenatal progesterone, also observed in patients with HDPs, drives inflammation and postpartum cardiac dysfunction. Antenatal (embryonic day 14.5), but not postpartum (postpartum day 28), progesterone treatment prevented postpartum cardiac dysfunction, identifying both a potential mechanistic and therapeutic strategy to reduce long-term maternal cardiovascular morbidity. Bert et al. show that inflammatory alterations associated with hypertensive disorders of pregnancy are linked to persistent postpartum cardiac dysfunction. Combining clinical and mechanistic studies, they identify reduced progesterone as a key driver and suggest antenatal progesterone supplementation as a potential strategy to mitigate long-term maternal cardiovascular risk.
Interleukin-6 (IL-6) signaling has been implicated in atherosclerotic cardiovascular disease (ASCVD), yet neutralizing IL-6 with ziltivekimab did not cut cardiovascular events in patients with ASCVD and chronic kidney disease in the ZEUS clinical trial. I explore possible explanations and implications for immune-targeting strategies in ASCVD.
Multiparametric phenotyping of TNNI3 variants in human induced pluripotent stem cell-derived cardiomyocytes provides a functional link between genetic variation, cardiac dysfunction, and clinical disease severity.
Myc is an evolutionarily conserved transcription factor that is necessary for the restoration of tissues in multiple regenerative species. The adult mammalian heart lacks regenerative capacity and cardiomyocytes fail to divide following damage-induced signaling. Transgenic expression of Myc and cyclin T1 can drive substantial adult cardiomyocyte proliferation to replace lost cardiomyocytes. Here, using transgenic models and a prototypical mRNA therapeutic, we show that Myc and cyclin T1 require transient induction for cardiomyocyte proliferation that leads to myocardial repair and functional recovery after myocardial infarction in mice. This research provides a strategy to translate Myc–cyclin T1 coexpression for cardiac regeneration to address serious unmet needs in the treatment of cardiovascular disease. Boikova et al. demonstrate transient in vivo coexpression of Myc and cyclin T1 using a modified mRNA approach, inducing adult cardiomyocyte proliferation and promoting myocardial repair and functional recovery following myocardial infarction in mice.
A brief, spatially restricted burst of Myc and cyclin T1 expression drives adult cardiomyocyte division and limits the loss of ventricular function after myocardial infarction in mice. How widely and for how long a regenerative program is switched on proves as decisive as how powerful that program is.